SEC Form 4
Praxis Precision Medicines, Inc. (PRAX) insider trading
In the 12 months to Nov 19, 2026, 3 PRAX insiders reported open-market sales of $11.1M across 3 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $11.1M
- 3 filings · 3 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 1 of 3
- $3.6M of $11.1M sold (33%)
Who traded PRAX, and when
- Sale
- Sale, pre-arranged (10b5-1)
PRAX daily close from Nov 19, 2025 to Nov 18, 2026, between $164.09 and $386.33, last $305.19. 3 sale and 0 purchase filings by 3 insiders, marked at their filing dates. Alex Nemiroff, General Counsel and Secretary: sold $4.9M across 1 filing, first filed Nov 21, 2025, last Nov 21, 2025. Jill DeSimone, Director: sold $3.6M across 1 filing, first filed Jun 26, 2026, last Jun 26, 2026. Lauren Mastrocola, Principal Accounting Officer: sold $2.6M across 1 filing, first filed Nov 21, 2025, last Nov 21, 2025.
Largest mark · tap a row for others
Alex Nemiroff · General Counsel and Secretary
Sale $4,852,256
25,130 shares at $193.09 avg
Filed Nov 21, 2025 · traded Nov 20
Close on filing date $169.80
Alex Nemiroff · General Counsel and Secretary
General Counsel and Secretary
$4.9M soldJill DeSimone · Director
Director
$3.6M soldLauren Mastrocola · Principal Accounting Officer
Principal Accounting Officer
$2.6M soldOpen-market trades
3 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Alex Nemiroff | General Counsel and Secretary | $4.9M | — | 1 | — | |
| Jill DeSimone | Director | $3.6M | — | 1 | 100% of sales | |
| Lauren Mastrocola | Principal Accounting Officer | $2.6M | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Jill DeSimone Director | SalePre-arranged (10b5-1) | 11,600 | $311.32 | $3.6M | 12,804 | |
traded | Lauren Mastrocola Principal Accounting Officer | Sale | 13,600 | $192.08 | $2.6M | 10,442 | |
traded | Alex Nemiroff General Counsel and Secretary | Sale | 25,130 | $193.09 | $4.9M | 20,832 |
GET /stocks/filings/vX/form-4?tickers=PRAX&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"PRAX"
],
"issuer_cik": "0001689548",
"owner_cik": "0001930479",
"accession_number": "0001930479-26-000003",
"form_type": "4",
"filing_date": "2026-06-26",
"period_of_report": "2026-06-24",
"issuer_name": "Praxis Precision Medicines, Inc.",
"issuer_trading_symbol": "PRAX",
"owner_name": "DeSimone Jill",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-24",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 320,
"transaction_price_per_share": 305.31,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 13487,
"transaction_value": 97699.2,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026."
},
{
"id": "F3",
"description": "The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"PRAX"
],
"issuer_cik": "0001689548",
"owner_cik": "0001930479",
"accession_number": "0001930479-26-000003",
"form_type": "4",
"filing_date": "2026-06-26",
"period_of_report": "2026-06-24",
"issuer_name": "Praxis Precision Medicines, Inc.",
"issuer_trading_symbol": "PRAX",
"owner_name": "DeSimone Jill",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-24",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 837,
"transaction_price_per_share": 315.705,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 2337,
"transaction_value": 264245.08499999996,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026."
},
{
"id": "F12",
"description": "The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 57 records
- Option exercises14 records
- Tax withholding13 records
- Grants and awards27 records
- Gifts3 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Praxis Precision Medicines, Inc.'s CEO sold stock?
No. Marcio Souza (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is PRAX’s insider data?
These are PRAX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track PRAX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for PRAX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.